LONDON & BOSTON--(BUSINESS WIRE)--Evaluate Ltd. will release a report on the Orphan Drug sector on Tuesday, April 23rd at the 2013 BIO International Convention. The report, which is based on EvaluatePharma® data complemented by commentary from EP Vantage, provides a strategic view of the Orphan Drug sector.
The analysis will include:
- Worldwide consensus sales performance to 2018 (Orphan Drug vs. Non-orphan)
- Industry R&D spend and timelines for Phase III (Orphan Drug vs. Non-orphan)
- Industry expected ROI for current Phase III and filed (Orphan Drug vs. Non-orphan)
- Top 20 Orphan Drug Designation Indications: EU, US
Evaluate (Booth #3840) will hold a press conference detailing the findings in the report at the 2013 BIO International Convention. Head of Research, Anthony Raeside and EP Vantage Editor, Lisa Urquhart, will be on hand to address questions.
Press Conference Details:
- Date: Tuesday, April 23rd
- Time: 11:00 a.m. CDT
- Location: Room S106A
A conference number will be made available for those media not attending BIO that are interested in participating in the press conference. Please refer to the media contacts for more details.
About Evaluate Ltd.
Established in 1996, Evaluate Ltd. is the leader in high quality life science sector analysis. EvaluatePharma delivers exclusive consensus forecasts and trusted commercial insight into biotech and pharmaceutical performance. EvaluateMedTech sets a new standard in integrated analysis and consensus forecasts of the global medical device and diagnostic industry. EvaluateClinical Trials delivers unique intelligence to efficiently and accurately analyze the global clinical trial landscape. A team of over 85 dedicated healthcare analysts employ rigorous methodologies to collate, organize and deliver the most-up-to-date commercial performance data available. An award winning editorial team of journalists writing under the EP Vantage name support EvaluatePharma’s analysis. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.